Clinical Trials
3 trialsNCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06182761 2023-12-27
WUKONG-9
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT04164745 2019-11-15
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Unknown